The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: A prospective survey

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Merli, Manuela ^a   Lucidi, Cristina ^a   Gregorio, Vincenza Di ^a   Falcone, Marco ^a   Giannelli, Valerio ^a   Lattanzi, Barbara ^a   Giusto, Michela ^a   Ceccarelli, Giancarlo ^a   Farcomeni, Alessio ^b   Riggio, Oliviero ^a   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; DRUG INDICATION; DRUG RESPONSE; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; URINARY TRACT INFECTION; AGED; BACTERIAL INFECTIONS; COMPLICATION; CROSS INFECTION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84930677242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127448     Document Type: Article

References (17)

1. Harbarth S, Albrich W, Goldmann DA, Huebner J. Lancet Infect Dis 2001; 1:251-261. PMID: 11871512
2. Zinn CS, Westh H, Rosdahl VT. Microb Drug Resist 2004; 10:160-168. PMID: 15256032
3. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010; 8:979-85. doi: 10.1016/j.cgh.2010.06.024 PMID: 20621200
4. Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56:825-32. doi: 10.1016/j.jhep.2011.11.010 PMID: 22173153
5. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55:1551-61. doi: 10.1002/hep.25532 PMID: 22183941
6. Harrison PF, Lederberg J. IOM eds 1998 (National Academy Press, Washington, DC), pp. 8-74.
7. Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, et al. Infect Control Hosp Epidemiol 1997; 18:275-291. PMID: 9131374
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81. doi: 10.1111/j.1469-0691.2011.03570.x PMID: 21793988
9. Di Gregorio V, Lucidi C, Giannelli V, Lattanzi B, Iacovone G, Giusto M, et al. Bacterial infections in cirrhotic patients: risk factors and rate of failure of the empirical antibiotic therapy. J of Hep 2014; 60: S215-S359.
10. Bartoletti M, Giannella M, Caraceni P, Domenicali M, Ambretti S, Tedeschi S, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J of Hep 2014; 61:51-58.
11. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7. PMID: 12435215
12. Venditti M, Falcone M, Corrao S, Licata G, Serra P, Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150:19-26. PMID: 19124816
13. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53:397-417. doi: 10.1016/j.jhep.2010.05.004 PMID: 20633946
14. Merli M, Lucidi C. Bacterial resistance in cirrhotic patients: an emerging reality. J Hepatol 2012; 56:756-7. doi: 10.1016/j.jhep.2011.12.004 PMID: 22230869
15. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148. PMID: 11786970
16. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56(6):2328-35. doi: 10.1002/hep.25947 PMID: 22806618
17. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:1-12. doi: 10.1086/595011 PMID: 19035777y of alpine plant species. Journal of Vegetation Science 15:77-84.